Abstract:Background: Pathological cardiac fibrosis and hypertrophy, the common features of left ventricular remodeling, often progress to heart failure. Forkhead box transcription factor P1 (Foxp1) in endothelial cells (ECs) has been shown to play an important role in heart development. However, the effect of EC-Foxp1 on pathological cardiac remodeling has not been well clarified. This study aims to determine the role of EC-Foxp1 in pathological cardiac remodeling and the underlying mechanisms. Methods: Foxp1 EC-specific loss-of-function and gain-of-function mice were generated, and an angiotensin II infusion or a transverse aortic constriction operation mouse model was used to study the cardiac remodeling mechanisms. Foxp1 downstream target gene transforming growth factor-beta 1 (TGF-beta 1) was confirmed by chromatin immunoprecipitation and luciferase assays. Finally, the effects of TGF-beta 1 blockade on EC-Foxp1 deletion-mediated profibrotic and prohypertrophic phenotypic changes were further confirmed by pharmacological inhibition, more specifically by RGD-peptide magnetic nanoparticle target delivery of TGF-beta 1-siRNA to ECs. Results: Foxp1 expression is significantly downregulated in cardiac ECs during angiotensin II-induced cardiac remodeling. EC-Foxp1 deletion results in severe cardiac remodeling, including more cardiac fibrosis with myofibroblast formation and extracellular matrix protein production, as well as decompensated cardiac hypertrophy and further exacerbation of cardiac dysfunction on angiotensin II infusion or transverse aortic constriction operation. In contrast, EC-Foxp1 gain of function protects against pathological cardiac remodeling and improves cardiac dysfunction. TGF-beta 1 signals are identified as Foxp1 direct target genes, and EC-Foxp1 deletion upregulates TGF-beta 1 signals to promote myofibroblast formation through fibroblast proliferation and transformation, resulting in severe cardiac fibrosis. Moreover, EC-Foxp1 deletion enhances TGF-beta 1-promoted endothelin-1 expression, which significantly increases cardiomyocyte size and reactivates cardiac fetal genes, leading to pathological cardiac hypertrophy. Correspondingly, these EC-Foxp1 deletion-mediated profibrotic and prohypertrophic phenotypic changes and cardiac dysfunction are normalized by the blockade of TGF-beta 1 signals through pharmacological inhibition and RGD-peptide magnetic nanoparticle target delivery of TGF-beta 1-siRNA to ECs. Conclusions: EC-Foxp1 regulates the TGF-beta 1-endothelin-1 pathway to control pathological cardiac fibrosis and hypertrophy, resulting in cardiac dysfunction. Therefore, targeting the EC-Foxp1-TGF-beta 1-endothelin-1 pathway might provide a future novel therapy for heart failure.

Osteoglycin Attenuates Cardiac Fibrosis by Suppressing Cardiac myofibroblast proliferation and migration throughAntagonizing LPA3/MMP2/EGFR signaling.

Osteoglycin attenuates cardiac fibrosis by suppressing cardiac myofibroblast proliferation and migration through antagonizing lysophosphatidic acid 3/matrix metalloproteinase 2/epidermal growth factor receptor signalling

A1304 Osteoglycin Attenuates Cardiac Fibrosis by Suppressing Cardiac myofibroblast proliferation and migration throughAntagonizing LPA3/MMP2/EGFR signalling

OS 36-06 OSTEOGLYCIN INHIBITS HYPERTENSIVE CARDIAC FIBROSIS THOUGH SUPPRESSION OF EGFR SIGNALING

Osteoglycin silencing exerts inhibitory effects on myocardial fibrosis and epithelial/endothelial-mesenchymal transformation in a mouse model of myocarditis

Osteoglycin prevents cardiac dilatation and dysfunction after myocardial infarction through infarct collagen strengthening

Suppression of OGN in lung myofibroblasts attenuates pulmonary fibrosis by inhibiting integrin αv-mediated TGF-β/Smad pathway activation

Osteoglycin prevents the development of age-related diastolic dysfunction during pressure overload by reducing cardiac fibrosis and inflammation

Loss Of Osteoglycin Promotes Angiogenesis In Limb Ischaemia Mouse Models Via Modulation Of Vascular Endothelial Growth Factor And Vascular Endothelial Growth Factor Receptor 2 Signalling Pathway

Inhibition of Osteopontin Reduce the Cardiac Myofibrosis in Dilated Cardiomyopathy Via Focal Adhesion Kinase Mediated Signaling Pathway.

Osteoglycin: An ECM Factor Regulating Fibrosis and Tumorigenesis

EGCG Inhibits CTGF Expression Via Blocking NF-κB Activation in Cardiac Fibroblast.

Endothelial Forkhead Box Transcription Factor P1 Regulates Pathological Cardiac Remodeling Through Transforming Growth Factor-β1–Endothelin-1 Signal Pathway

Inhibitory Effects of Oxymatrine on TGF-β1-induced Proliferation and Abnormal Differentiation in Rat Cardiac Fibroblasts Via the P38mapk and ERK1/2 Signaling Pathways

Osteoprotegerin/Rank/Rankl Axis in Cardiac Remodeling Due to Immuno-Inflammatory Myocardial Disease

Oleic Acid Attenuates Ang II (angiotensin II)-Induced Cardiac Remodeling by Inhibiting FGF23 (fibroblast Growth Factor 23) Expression in Mice

Osteoglycin (OGN) reverses epithelial to mesenchymal transition and invasiveness in colorectal cancer via EGFR/Akt pathway

High-Mobility Group A1 Promotes Cardiac Fibrosis by Upregulating FOXO1 in Fibroblasts

GW27-e0274 MicroRNA181a Regulates Osteopontin Expression and Cardiac Fibrosis in Mice

Nogo-C Regulates Post Myocardial Infarction Fibrosis Through the Interaction with ER Ca2+ Leakage Channel Sec61α in Mouse Hearts

Effects of Osteoglycin (OGN) on treating senile osteoporosis by regulating MSCs